(AGENPARL) – Thu 03 July 2025 Lund, Sweden, 3 July 2025. Hansa Biopharma, “Hansa” (Nasdaq Stockholm: HNSA),
will publish its interim report for January – June 2025 on 17 July 2025.
Interested parties may join the Company’s quarterly conference call on the same
date at 14:00 CEST/8:00 AM ET. The event will be hosted by Renée Aguiar
-Lucander, CEO, Evan Ballantyne, CFO, Hitto Kaufmann, CR&DO, and Maria Törnsén
COO and President U.S. The call will include a review of the interim results and
a business and pipeline update. It will be held in English.
Slides used in the presentation will be made available on the company website at
the following link: Financial
reports (https://www.hansabiopharma.com/investors/financial-reports/).
To participate in the telephone conference, please use the dial-in details
provided below:
Participant Dial In (Toll Free): 1-833-821-3542
Participant International Dial In: 1-412-652-1248
The webcast will be available on:
https://event.choruscall.com/mediaframe/webcast.html?webcastid=hUSedAeI (https://
eur03.safelinks.protection.outlook.com/?url=https%3A%2F%2Fevent.choruscall.com%2F
mediaframe%2Fwebcast.html%3Fwebcastid%3DhUSedAeI&data=05%7C02%7Cfilippo.guizzetti
nRydWUsIlYiOiIwLjAuMDAwMCIsIlAiOiJXaW4zMiIsIkFOIjoiTWFpbCIsIldUIjoyfQ%3D%3D%7C0%7
C%7C%7C&sdata=9fnn41cX3IxJijyq05gW3XCi8GC%2B29w70m0nop8TDoY%3D&reserved=0)
— ENDS —
Contacts for more information:
Evan Ballantyne, Chief Financial Officer
Stephanie Kenney, VP Global Corporate Affairs
Notes to editors
About Hansa Biopharma
Hansa Biopharma AB is a pioneering commercial-stage biopharmaceutical company on
a mission to develop and commercialize innovative, lifesaving and life-altering
treatments for patients with rare immunological conditions. The company has a
rich and expanding research and development program based on its proprietary IgG
-cleaving enzyme technology platform, to address serious unmet medical needs in
autoimmune diseases, gene therapy and transplantation. The company’s portfolio
includes imlifidase, a first-in-class immunoglobulin G (IgG) antibody-cleaving
enzyme therapy, which has been shown to enable kidney transplantation in highly
sensitized patients and HNSA-5487, a next-generation IgG cleaving molecule with
redosing potential. Hansa Biopharma is based in Lund, Sweden, and has operations
in Europe and the U.S. The company is listed on Nasdaq Stockholm under the
ticker HNSA. Find out more at http://www.hansabiopharma.com and follow us on
LinkedIn (https://www.linkedin.com/company/hansa-medical-ab/).
©2025 Hansa Biopharma AB. Hansa Biopharma, the beacon logo, IDEFIRIX, and
IDEFIRIX flower logo are trademarks of Hansa Biopharma AB, Lund, Sweden. All
rights reserved.
If you would rather not receive future communications from Hansa Biopharma AB, please go to https://optout.ne.cision.com/en/bNY6NA2hq8HseXDeaAmdm39y7zu3Jdim1MQrKzqp36hhQAjX93krU4dH6udija4cihr7EhxaFrMy5gQuzsKB9Fh25PADqYG7bQuXQVqoxv7jd.
Hansa Biopharma AB, Scheelevägen 22, Lund, 22362 Sweden
————————————————————
This information was brought to you by Cision http://news.cision.com
The following files are available for download:
If you would rather not receive future communications from Hansa Biopharma AB, please go to https://optout.ne.cision.com/en/bNY6NA2hq8HseXDeaAmdm39y7zu3Jdim1MQrKzqp36hhQAjX93krU4dH6udija4cihr7EhxaFrMy5gQuzsKB9Fh25PADqYG7bQuXQVqoxv7jd.
Hansa Biopharma AB, Scheelevägen 22, Lund, 22362 Sweden
Report this content